EIT Pharma Closes Oversubscribed $35 Million Series A Round, Led by Propel Bio Partners
EIT Pharma, Inc. ("EIT Pharma" or the "Company"), a biotechnology company focused on developing therapies for infectious diseases, today announced the successful close of an oversubscribed $35 million Series A financing round. The round was led by Propel Bio Partners, with participation from Good Ventures, Arrowtown, and others.
EIT Pharma Announces FDA Acceptance of New Drug Application for Lonafarnib for Treatment of Chronic Hepatitis D
EIT Pharma, Inc. (“EIT Pharma” or the “Company”), a biotechnology company focused on developing therapies for infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for lonafarnib for the treatment of chronic hepatitis D.
EIT Pharma Highlights New Lonafarnib Analyses at EASL Congress 2026
EIT Pharma presented new analyses from the lonafarnib development program for Chronic Hepatitis Delta (CHD) at EASL Congress 2026 in Barcelona, Spain, held May 27–30, 2026. Due to the high unmet medical need in CHD, EIT Pharma resurrected the development of lonafarnib as the only late-stage oral option in late-stage development.